Media headlines about ProPhase Labs (NASDAQ:PRPH) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProPhase Labs earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.3855132033384 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

ProPhase Labs (NASDAQ:PRPH) traded down $0.06 during midday trading on Wednesday, hitting $2.24. The stock had a trading volume of 13,900 shares, compared to its average volume of 21,419. ProPhase Labs has a 12 month low of $1.78 and a 12 month high of $2.45. The firm has a market capitalization of $27.22, a PE ratio of 2.99 and a beta of 0.16.

ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.05) earnings per share for the quarter. ProPhase Labs had a return on equity of 40.36% and a net margin of 307.58%. The company had revenue of $3.04 million during the quarter.

ProPhase Labs declared that its board has authorized a share buyback program on Friday, November 10th that authorizes the company to repurchase 1,700,000 shares. This repurchase authorization authorizes the company to repurchase shares of its stock through a tender offer. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Separately, ValuEngine cut ProPhase Labs from a “hold” rating to a “sell” rating in a report on Thursday, October 5th.

In other news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $2.30, for a total value of $824,828.30. Following the completion of the transaction, the chief financial officer now directly owns 132,703 shares of the company’s stock, valued at $305,216.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Braden Michael Leonard sold 1,695,305 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $2.30, for a total value of $3,899,201.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,423,255 shares of company stock valued at $5,573,487. Insiders own 29.60% of the company’s stock.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ProPhase Labs (PRPH) Share Price” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-prophase-labs-prph-share-price.html.

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Insider Buying and Selling by Quarter for ProPhase Labs (NASDAQ:PRPH)

Receive News & Stock Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related stocks with our FREE daily email newsletter.